Payment overview · 2025
General Payments
$861.20
44 reported records · 12 companies
Healthcare provider profile · identity verified
Brian Lee Quarton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GILLESPIE, IL · NPI 1417951401
Verified facts
What the public records show
CMS Open Payments records show Brian Lee Quarton, M.D. received $861.20 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.95 | 19.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.58 | 16.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.52 | 13.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.49 | 12.1% | 5 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $62.58 | 7.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.87 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.83 | 6.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $49.78 | 5.8% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $41.58 | 4.8% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $25.66 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.40 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.96 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $861.20 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.58 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $95.45 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.83 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.23 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.62 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.62 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $66.03 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $62.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $49.78 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.49 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $41.58 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $41.58 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 274 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
274 | 32 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
274 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 589 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 82 |
| Gabapentin | Gabapentin | 321 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 52 |
| Lisinopril | Lisinopril | 295 | 63 |
| Eliquis | Apixaban | 274 | 32 |
| Furosemide | Furosemide | 273 | 49 |
| Potassium Chloride | Potassium Chloride | 251 | 32 |
| Sertraline Hcl | Sertraline Hcl | 243 | 40 |
| Omeprazole | Omeprazole | 239 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 210 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 41 |
| Losartan Potassium | Losartan Potassium | 203 | 39 |
| Metformin Hcl Er | Metformin Hcl | 199 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 190 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 30 |
| Trazodone Hcl | Trazodone Hcl | 175 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 41 |
| Carvedilol | Carvedilol | 155 | 33 |
| Irbesartan | Irbesartan | 145 | 30 |
| Simvastatin | Simvastatin | 145 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 24 |
| Memantine Hcl | Memantine Hcl | 136 | 18 |
| Montelukast Sodium | Montelukast Sodium | 120 | 17 |
| Allopurinol | Allopurinol | 115 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 113 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 110 | 26 |
| Donepezil Hcl | Donepezil Hcl | 102 | 15 |
| Finasteride | Finasteride | 99 | 22 |
| Famotidine | Famotidine | 98 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 14 |
| Buspirone Hcl | Buspirone Hcl | 94 | 14 |
| Spironolactone | Spironolactone | 94 | 17 |
| Jardiance | Empagliflozin | 86 | 17 |
| Meloxicam | Meloxicam | 80 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 19 |
| Celecoxib | Celecoxib | 74 | 17 |
| Mirtazapine | Mirtazapine | 74 | suppressed |
| Azithromycin | Azithromycin | 72 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 69 | suppressed |
| Metformin Hcl | Metformin Hcl | 68 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Prednisone | Prednisone | 54 | 26 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Cephalexin | Cephalexin | 51 | 29 |
| Baclofen | Baclofen | 50 | suppressed |
| Alprazolam | Alprazolam | 49 | suppressed |
| Lovastatin | Lovastatin | 49 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 11 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Torsemide | Torsemide | 41 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | 11 |
| Ozempic | Semaglutide | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Primidone | Primidone | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 14 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 13 |
| Cefuroxime | Cefuroxime Axetil | 23 | 14 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Dofetilide | Dofetilide | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Nystatin | Nystatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $861.20 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, BRIXADI, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, UBRELVY, VRAYLAR, YUPELRI, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error